Journal of Clinical Oncology
Articles in this Issue
A real world study of dysgeusia-related factors in head and neck cancer patients undergoing radiotherapy.
e18146 Background: Dysgeusia, defined as altered taste perception, is a common but often overlooked side effect in head and neck cancer (HNC) treatment. I...
Lipid metabolic gene expression and association with decreased overall survival and immunogenicity in <i>KRAS-STK11</i> NSCLC.
8534 Background: Approximately 30% of patients (pts) with non-small cell lung cancer (NSCLC) have alterations (alt) in KRAS . How...
Trend of <i>Clostridium difficile</i> colitis infection and ileus among patients admitted to the hospital with common malignancies in 2022: An analysis of the National Inpatient Sample.
e24036 Background: Clostridium difficile (C. difficile) infection is a prevalent condition with a high mortality risk, particularly among immu...
Impact of antecedent myelodysplastic syndrome treatment on outcomes and treatment response in patients with subsequent secondary acute myeloid leukemia.
e18516 Background: Secondary acute myeloid leukemia (sAML) is a diagnostic qualifier of AML that develops in patients previously diagnosed with a myeloid...
Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer: Data from 30 health systems in the United States.
3613 Background: Incidence of early-onset colorectal cancer (EoCRC) in patients without any family history has been increasing in recent years. Our study...
Evaluating three-month survival benefit of inpatient chemotherapy in a safety-net hospital.
e13534 Background: Safety-net hospitals treat underprivileged and vulnerable population, most of whom are uninsured/underinsured. This often poses barrier...
TACE-HAlC combined with donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): A retrospective IPTW adjusted cohort study.
4090 Background: Transarterial chemoembolization (TACE) combined with hepatic arterial infusion chemotherapy (HAIC) has demonstrated superior objective re...
ctDNA-guided treatment stratification for nasopharyngeal carcinoma patients: A retrospective cohort.
e18071 Background: Liquid biopsy based on circulating tumor DNA (ctDNA) has recently been used to treat various cancers. Studies on the use of ctDNA in na...
Patient and clinician expert perspectives on the impactful symptoms of head and neck squamous cell carcinoma and its treatment.
e18001 Background: Head and neck squamous cell carcinoma(HNSCC) and its treatments affect health-related quality of life. This study aimed to describe pat...
Unveiling the hidden burden: Prevalence and disparities of cancer diagnosed in emergency and hospital settings.
e13748 Background: Patients diagnosed with cancer while inpatient (Emergency Department [ED] or hospital) have worse outcomes than those diagnosed as outp...
OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma.
9519 Background: Non-engineered TIL cell therapy is approved for ICI-resistant advanced melanoma, but requires co-administration of toxic high-dose IL2. O...
Clinical and pathological characteristics of primary duodenal adenocarcinoma and the construction of predictive models in China and SEER database.
e16472 Background: Primary duodenal adenocarcinoma (DA) is a rare tumor with a low incidence rate, high mortality rate, and lacks effective treatment meth...
Efficacy and safety of transcatheter arterial infusion of immune checkpoint inhibitors in locoregional unresectable or in-transit acral melanoma: A multi-center real-world study.
9546 Background: Acral melanoma (AM) is highly invasive. Standard treatment options, including surgical resection and systemic immunotherapy, frequently y...
Rethinking future workforce planning by developing novel metrics of complexity in cancer care.
9015 Background: The decision to recruit additional oncologists is often based on simple workload measures such as new patient volumes. This approach may...
Textbook outcomes in liver surgery: A decade of experience at a cancer-dedicated centre.
e16260 Background: Surgical resection is the main treatment for both primary and metastatic liver cancers, but it comes with notable risks of complication...
Comparison of <sup>68</sup> Ga-NY104 PET/CT with <sup>18</sup> F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, comparative phase II study.
4524 Background: 68 Ga-NY104 is a small-molecule PET agent selectively targeting carbonic anhydrase IX (CAIX), which is highly expressed on cl...
Association of immune, proliferation gene signatures and stromal tumor infiltrating lymphocytes (sTILs) with outcomes in patients with stage I triple-negative breast cancer (TNBC).
553 Background: Approximately one third of all TNBC diagnoses are stage 1. No validated biomarker is routinely utilized to guide treatment at this early s...
Incidence and survival trends in adolescents and young adults with carcinoma of unknown primary: Insights from the SEER database (2000–2021).
e22586 Background: Carcinoma of Unknown Primary (CUP) among adolescents and young adults (AYA, ages 15–39) poses unique challenges due to diagnostic uncer...
Economic evaluation of work productivity gains associated with ribociclib (RIB) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) in the United States.
e23117 Background: Despite treatment with standard-of-care adjuvant endocrine therapy, many patients with HR+/HER2− EBC continue to experience recurrences...
Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
5600 Background: In Part 1 of the phase 3 RUBY trial (NCT03981796) in pts with pA/rEC, dostarlimab + carboplatin-paclitaxe...
Efficacy and safety of oral NEPA versus fosaprepitant combined with palonosetron for preventing highly emetogenic chemotherapy-induced nausea and vomiting in patients with nasopharyngeal carcinoma.
e18075 Background: Oral NEPA, a fixed combination of netupitant (300 mg) and palonosetron (0.5 mg), is a highly effective antiemetic agent used in patient...
Deep learning-based contouring of Couinaud segments on CT: Utility for volumetric analysis of future liver remnant.
4113 Background: Hepatocellular carcinoma (HCC) is the most common primary liver tumor, and the liver is a frequent site of metastasis of other cancers. H...
Long-term survival analysis comparison of radical antegrade modular pancreatectomy (RAMPS) and standard retrograde pancreatectomy (SPRS): Based on LASSO Cox regression prediction model.
e16437 Background: This study aims to evaluate the advantages of radical anterograde modular pancreatictomy (RAMPS) over standard retrograde pancreatictom...
Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE).
TPS2090 Background: Patients with non-small cell lung cancer (NSCLC) with ALK rearrangements have a high frequency of brain metastases. Alectinib was show...
Novel potent and selective inhibitors targeting FLT3 for AML therapy.
6542 Background: Acute Myeloid Leukemia (AML) is a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 inter...